Racura Oncology has received approval to escalate the dosage of its drug RC220 in the HARNESS-1 trial, aimed at treating EGFR-mutant lung cancer, marking a significant step in cancer research.

Racura Oncology has begun the HARNESS-1 Phase 1 clinical trial, examining RC220 combined with osimertinib in EGFR-mutant non-small cell lung cancer.

Race Oncology (ASX:RAC) has executed an $8.6 million contract with George Clinical International to support the RAC-010 Phase 1 trial of RC220 bisantrene in

Watch the presentations from three ASX-listed biotechs at the forefront of promising new cancer therapies, each advancing treatments for diseases with significant unmet medical need. Inquiries: info@monsoon.com.au The session includes company updates, pipeline progress and outlook discussions from: ✅ 03:00 Racura Oncology (ASX: RAC) Racura is a Phase 3 clinical-stage company advancing RC220 across three active oncology programs. RC220 has been discovered to silence MYC — a target implicated in 70% of all cancers and long considered undruggable — via DNA G4 binding. Active programs include a Phase 3 AML trial, the HARNESS-1 Phase 1 trial in EGFR-mutant NSCLC combining RC220 with Tagrisso®, and the CPACS-1 cardioprotection trial with patients already dosed in Hong Kong and Australia. First patient dosed in both Phase 3 AML and HARNESS-1 are targeted in 2026, with HARNESS-1 carrying explicit potential for FDA Accelerated Approval. Website: https://www.racuraoncology.com/ ✅ 25:44 Amplia Therapeutics (ASX: ATX | OTCQB: INNMF) Amplia is a clinical-stage Australian biotech developing best-in-class FAK inhibitors for fibrotic cancers. Its lead drug narmafotinib has delivered 5 confirmed complete responses in advanced pancreatic cancer — a 7.8% complete response rate confirmed by independent central review, compared to 0.2% for chemotherapy alone, and never before seen in this indication. The ACCENT trial achieved a 36% objective response rate and median overall survival of 11.1 months. A registration-enabling Phase 2b study is now underway, designed in alignment with FDA feedback, with a new ovarian cancer trial (PRROSE) and kRAS inhibitor partnering discussions further expanding the pipeline. Website: https://www.ampliatx.com ✅ 47:45 Prescient Therapeutics (ASX: PTX) Prescient is developing the world's only GGTase-1 inhibitor in clinical development — a first-in-class targeted therapy advancing through Phase 2a in Cutaneous T-Cell Lymphoma (CTCL), a blood cancer with no satisfactory treatment options. Phase 1b results in CTCL delivered a 43% response rate, 100% clinical benefit rate, 12.4-month duration of response, and zero serious treatment-related adverse events. The Phase 2a trial has enrolled 18 patients across 12 active sites in Australia, the US and Italy, scaling toward 16 sites globally. GGTase-1 biology is implicated in approximately 22% of all cancers, with the CTCL market forecast at ~US$1.2bn annually by 2034. Website: https://www.ptxtherapeutics.com

Race Oncology (ASX:RAC) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Race Oncology’s share price, chart, trading

Race Oncology (ASX:RAC) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Race Oncology’s share price, chart, trading

<a href='https://grafa.com/company/race-oncology-ltd-3890'>Race Oncology</a> <a href='https://grafa.com/asset/race-oncology-ltd-3890-rac.asx'>(ASX:RAC)</a> h

Race Oncology (ASX:RAC) announced the activation of a second clinical trial site at the Central Coast Local Health District (Gosford and Wyong Hospitals) for

<a href='https://grafa.com/company/race-oncology-ltd-3890'>Race Oncology</a> <a href='https://grafa.com/asset/race-oncology-ltd-3890-rac.asx'>(ASX:RAC)</a> a

<a href='https://grafa.com/company/race-oncology-ltd-3890'>Race Oncology</a> <a href='https://grafa.com/asset/race-oncology-ltd-3890-rac.asx'>(ASX:RAC)</a> h

<a href='https://grafa.com/company/race-oncology-ltd-3890'>Race Oncology</a> <a href='https://grafa.com/asset/race-oncology-ltd-3890-rac.asx'>(ASX:RAC)</a>,

Race Oncology (ASX:RAC) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Race Oncology’s share price, chart, trading

Race Oncology (ASX:RAC) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Race Oncology’s share price, chart, trading

Race Oncology (ASX:RAC) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Race Oncology’s share price, chart, trading

Race Oncology (ASX:RAC) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Race Oncology’s share price, chart, trading

Race Oncology (ASX:RAC) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Race Oncology’s share price, chart, trading

Race Oncology (ASX:RAC) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Race Oncology’s share price, chart, trading

Racura Oncology has dosed the first patient in the Phase Ia/b HARNESS-1 trial assessing a combination of RC220 and osimertinib for EGFR-mutant NSCLC.

Racura Oncology starts Harness-1 Phase 1 with first patient dosed for RC220 + osimertinib in EGFR-mutant NSCLC; early safety data awaited.

Racura Oncology advances RC220 CPACS trial to 80mg/m2 as SRC clears Cohort 2; updated cardioprotection protocol; A$19.38m cash runway to CY2027.

Racura Oncology (ASX:RAC) final patient in first cohort dosed with RC220 in cardioprotection and anticancer synergy.

Racura Oncology (ASX:RAC) receives governance approval to launch its HARNESS-1 clinical trial assessing the safety and tolerability of R22.

Racura Oncology wins HARNESS-1 Phase 1a/b governance approval for RC220/osimertinib in EGFR-mutant NSCLC, enabling site initiation and recruitment.

Race Oncology (ASX:RAC) has identified major new opportunities in two new cancer indications for its RC220 therapy.